Pseudomonas aeruginosa is a gram-negative pathogen causing life-threatening infections. Lung injury and the development of sepsis depend largely on the expression of type III secretion system (TTSS) virulence. TTSS functions as a molecular syringe to deliver toxins directly to the cytosol of cells, inhibit innate immune mechanisms, and prevent bacterial clearance. Polyclonal antibodies that bind to PcrV of P. aeruginosa inhibit the delivery of type III toxins and enhance the clearance of bacteria during acute lung infections. PcrV is a homologue of LcrV, a protective antigen in the Yersinia TTSS and an integral component of TTSS. In this study, a murine monoclonal antibody (MAb) to PcrV was generated: MAb 166, which is protective against P. aeruginosa when coinstilled with the bacterial inoculum or intraperitoneally transferred to mice. Fab fragments from MAb 166 prevent sepsis and death. The epitope bound by MAb 166 was mapped to the carboxyl-terminus of PcrV.

Download full-text PDF

Source
http://dx.doi.org/10.1086/341069DOI Listing

Publication Analysis

Top Keywords

mab 166
12
monoclonal antibody
8
pseudomonas aeruginosa
8
type iii
8
pcrv
5
generation characterization
4
characterization protective
4
protective monoclonal
4
antibody pseudomonas
4
aeruginosa
4

Similar Publications

Purpose: Determine if molecular classification using mismatch repair (MMR) and p53 protein expression predicts recurrence-free survival (RFS) and overall survival (OS) in endometrial cancer (EC) patients treated with chemotherapy and radiation (CRT) versus chemotherapy (CT).

Methods: GOG-0258, a phase III randomized trial (NCT00942357), compared CRT to CT. Immunohistochemistry assessed MMR and p53 status.

View Article and Find Full Text PDF

Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) have demonstrated promising effects in lowering cardiovascular incidents among patients with acute coronary syndrome. However, their influence on early platelet reactivity after primary percutaneous coronary intervention (PPCI) remains unclear.

Objectives: This research sought to investigate the effects of entirely human anti-PCSK9 antibodies on platelet function as measured by thrombelastography and 12-month postoperative results in patients receiving PPCI and treated with ticagrelor-based dual antiplatelet therapy.

View Article and Find Full Text PDF

Aims: Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9 mAbs) are recommended for high-risk patients if the low-density lipoprotein cholesterol (LDL-C) targets are not achieved with statins and ezetimibe. We studied persistence and adherence to 1) PCSK9 mAbs and 2) statins and ezetimibe in a nationwide cohort of incident PCSK9 mAb users.

Methods And Results: Information on all PCSK9 mAb users ≤80 years from 2015 through 2023 were extracted from the Norwegian Drug Registry.

View Article and Find Full Text PDF
Article Synopsis
  • Statins are a primary treatment for heterozygous familial hypercholesterolemia, but there's concern they may increase the risk of type 2 diabetes; however, some studies suggest these patients might actually have a lower prevalence of diabetes.
  • A worldwide study analyzed data from nearly 25,000 adults with heterozygous familial hypercholesterolemia, looking at factors like age, BMI, and diabetes status while excluding certain groups to focus on the risk of type 2 diabetes.
  • The results showed a 5.7% prevalence of type 2 diabetes in the overall population studied, with a lower rate of 4.1% among those with genetically confirmed heterozygous familial hypercholesterolemia
View Article and Find Full Text PDF
Article Synopsis
  • * The research included over 56,000 primary total knee arthroplasties (TKAs) performed from 2010 to 2018, analyzing the identification and reporting of PJI cases through sensitivity, specificity, and predictive values.
  • * Findings indicated that DKR had a sensitivity of only 58% for PJI revisions, with the cumulative incidence of PJI at 0.8% for DKR, 0.9% for HAIBA, and 1
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!